MedTech Industry Expansion: NAMSA Acquires WuXi AppTec’s U.S. Testing Operations
NAMSA, a leading global provider of testing, clinical, and regulatory services for the MedTech industry, has announced an agreement to acquire the medical device testing facilities of WuXi AppTec located in Minnesota and Georgia. This strategic acquisition is aimed at expanding NAMSA’s portfolio of clinical research and testing solutions, enabling the company to better serve its clients in the MedTech space.
André-Michel Ballester, CEO of NAMSA, expressed his enthusiasm about the deal, emphasizing the complementary nature of both companies’ expertise. “We are extremely pleased to announce our agreement with WuXi AppTec, as it enables us to expand our portfolio of clinical research and testing solutions for clients,” said Ballester. He further explained that while both companies operate in the medical device testing sector, they have distinct areas of expertise that, when combined, will enhance the client experience. According to Ballester, this acquisition will accelerate innovation in the MedTech field and help sponsors deliver life-saving medical technology worldwide.
The MedTech industry, particularly in the United States, is experiencing increasing regulatory scrutiny and heightened demands for clinical evidence. These factors can often lead to delays in product development, rising costs, and slower market entry. NAMSA’s comprehensive suite of outsourcing and in-house services helps innovators mitigate these challenges by reducing risks, shortening time to market, and ultimately increasing stakeholder value.
With the acquisition, NAMSA and WuXi AppTec will work closely to ensure a seamless transition for both employees and customers, minimizing disruption and maintaining high levels of service quality throughout the process.
NAMSA’s acquisition of WuXi AppTec’s U.S. Medical Device Testing Operations is a significant milestone in the company’s growth. This deal marks the 9th acquisition since NAMSA became part of ARCHIMED, a healthcare-focused global private equity firm, in 2020. ARCHIMED’s investment expertise has helped NAMSA enhance its global presence and capabilities in the MedTech sector, positioning the company as a trusted partner in medical device development and commercialization.
About NAMSA: Founded in 1967, NAMSA is a leading global provider of testing, clinical, and regulatory consulting services for the medical device industry. The company has a deep pool of experts and extensive therapeutic knowledge, which allows it to accelerate product development and help clients navigate the complexities of the regulatory landscape. From preclinical and clinical research to medical device testing and regulatory compliance, NAMSA is dedicated to supporting medical device sponsors in successfully bringing their products to market. As the MedTech industry continues to evolve, NAMSA remains a trusted partner for organizations looking to achieve successful commercialization outcomes. More information about NAMSA can be found on their website: namsa.com.
About WuXi AppTec: WuXi AppTec is a global company that offers a wide range of research and development services to the pharmaceutical and life sciences industries. With operations across Asia, Europe, and North America, the company provides an integrated, end-to-end platform for drug discovery, development, and manufacturing. WuXi AppTec’s services include chemistry, biology, preclinical testing, clinical research, and contract manufacturing solutions.
The company is committed to advancing healthcare by enabling customers to develop new treatments more efficiently and cost-effectively. WuXi AppTec serves over 6,000 customers in more than 30 countries, supporting their efforts to improve patient health and address critical medical needs. The company has also earned an AA ESG (Environmental, Social, and Governance) rating from MSCI for the fourth consecutive year in 2024.
About ARCHIMED: ARCHIMED is a private equity firm specializing in healthcare investments. With offices in Europe, North America, and Asia, the firm has a broad focus on healthcare industries, including biopharma, MedTech, healthcare IT, and life sciences tools. ARCHIMED’s expertise spans across operational, scientific, medical, and financial domains, allowing it to serve as both a strategic and financial partner to its portfolio companies. With an €8 billion portfolio, ARCHIMED helps its partners grow internationally, innovate, and expand their products and services. The firm is also committed to impact investing through initiatives like its EURÊKA Foundation.
By combining the strengths of NAMSA and WuXi AppTec, this acquisition represents a significant step forward in enhancing the capabilities and services offered to the MedTech sector, ultimately driving innovation and helping deliver vital medical technologies to the market more efficiently.
